STOCK TITAN

Rhythm Pharmaceuticals (RYTM) Revenue by Year

RYTM NASDAQ

Rhythm Pharmaceuticals, Inc. generated $189.8M in revenue in fiscal year 2025. This represents an increase of 45.8% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $280.7M in revenue. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Rhythm Pharmaceuticals, Inc. has filed alongside them.

FY2025 annual
Revenue $189.8M
YoY +45.8%
5Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RYTM Revenue by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-K
Revenue$280.7M$189.8M+45.8%$130.1M+68.1%$77.4M+227.6%$23.6M+649.5%$3.2Mn/m$0n/m$0n/m$0n/m$0n/m$0N/A

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

RYTM Revenue by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Revenue$92.1M+79.6%$71.3M+46.9%$60.1M+83.8%$57.3M+36.9%$51.3M+54.3%$48.5M+66.8%$32.7M+25.9%$41.8M+72.6%$33.3M+47.8%$29.1M+51.3%$26.0M+126.4%$24.2M+175.7%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Rhythm Pharmaceuticals, Inc. financials

Frequently Asked Questions

Rhythm Pharmaceuticals, Inc. generated $189.8M in revenue in fiscal year 2025.

Rhythm Pharmaceuticals, Inc. (RYTM) revenue rose by 45.8% year over year, from $130.1M to $189.8M in fiscal year 2025.

Rhythm Pharmaceuticals, Inc. (RYTM) reported $280.7M in revenue over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Rhythm Pharmaceuticals, Inc. (RYTM) reported $92.1M in revenue in Q3 2026. This represents an increase of 79.6% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Rhythm Pharmaceuticals, Inc. (RYTM) reported on that line in every period on record.